SCHEMBL1338617

SCHEMBL1338617

Cn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c3cc(-c4nccs4)ccc3n(C)c21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 1/20 0.39
▸ CHEK1 O14757 1/20 0.38
▸ HSD11B1 P28845 3/20 0.37
▸ GABRA1 P14867 5/20 0.37
▸ GABRG2 P18507 4/20 0.37
▸ GABRB3 P28472 4/20 0.37
▸ GABRA3 P34903 1/20 0.37
▸ GABRA2 P47869 1/20 0.37
▸ F2RL3 Q96RI0 1/20 0.36
▸ TNKS O95271 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ CNR1 P21554 6/20 0.36
▸ CNR2 P34972 6/20 0.36
▸ GABRA5 P31644 3/20 0.34
▸ RIPK2 O43353 1/20 0.34
▸ NOD2 Q9HC29 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4761794 0.83 KDM4E (0.35) HSD11B1GABRA1GABRG2GABRB3F2RL3
SCHEMBL1339227 0.83 GABRA1 (0.41) HSD11B1GABRA1GABRG2GABRB3GABRA3
SCHEMBL1338076 0.83 CNR1 (0.40) HSD11B1GABRA1F2RL3KDM4EALDH1A1
SCHEMBL1339352 0.82 TLR8 (0.39) KDRCHEK1HSD11B1GABRA1GABRG2
SCHEMBL1339138 0.82 KDM4E (0.48) HSD11B1KDM4EALDH1A1GAAHPGD
SCHEMBL1338674 0.81 F2RL3 (0.37) HSD11B1GABRA1GABRG2GABRB3F2RL3
SCHEMBL1338957 0.81 GFER (0.44) GABRA1GABRG2GABRB3KDM4EALDH1A1
SCHEMBL1338217 0.81 SHMT1 (0.40) GABRA1KDM4ECNR1CNR2EGFR
SCHEMBL1336852 0.81 SHMT1 (0.38) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1338764 0.80 BRD4 (0.41) HSD11B1GABRA1GABRG2GABRB3F2RL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 KDR 1229/4885CHEK1 1883/4885HSD11B1 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback